Investigation of Milk Peptides on Postprandial Blood Glucose Profile
Investigation of Milk Peptides on Postprandial Blood Glucose Profile: Randomized, Double-blind, Placebo-controlled, Cross-over Study With Different Dosages Followed by an Open-label Single Arm Phase to Estimate Long Term Effects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Esslingen, Germany
- BioTeSys
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects with prediabetic HbA1c values between 5.7% - 6.4% and/or Fasting blood glucose ≥ 5.6 mmol/l (≥ 100 mg/dl) und < 7.0 mmol/l (< 125 mg/dl) (in venous plasma)
- Age: 30-70 years
- Body mass index 19-35 kg/m2
- Non-smoker
- Caucasian
- Availability and presence in the study unit for approx. 3.5 hours/ week for 3 times in a row with approx. 1 week of washout in between.
- Signed informed consent form
- No changes in food habits or physical activity 3 months prior to screening and during the study
Exclusion Criteria:
- Presence of disease or drug(s) influencing digestion and absorption of nutrients or bowel habits
- Intake of medications known to affect glucose tolerance, e.g., diabetic medication, steroids, protease inhibitors or antipsychotics
- Diagnosed Typ 2-Diabetics with medical treatment
- Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the investigator's opinion would impact patient safety
- Severe liver, renal or cardiac disease
- Acute gastrointestinal diseases including diarrhea and/or vomiting within the last 2 weeks
- Known inflammatory and malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis)
- Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs
- Major medical or surgical event requiring hospitalization within the previous 3 months
- Intake of antibiotics within 4 weeks before the test days
- Known alcohol abuse or drug abuse
- Pregnant or breast feeding women
- Known or suspected allergy to any component of the investigational product(s) (e.g. milk protein)
- Known HIV-infection
- Known acute or chronic hepatitis B and C infection
- Blood donation within 4 weeks prior to visit 1 or during the study
- Subject unable to co-operate adequately
- Participation in a clinical study with an investigational product within one month before start of study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
maltodextrin
|
what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
|
|
Active Comparator: High dose Milk peptides
2800mg of whey protein hydrolysates single dose
|
what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
|
|
Active Comparator: Low dose Milk peptides
1400mg of whey protein hydrolysate Single dose and 6 weeks intervention
|
what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose-iAUC(0-180min)
Time Frame: day 1, day 8, day 15, day 57
|
Area under the curve calculated as the incremental area under the blood glucose response curve, ignoring the area beneath the fasting concentration
|
day 1, day 8, day 15, day 57
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: day 1, day 8, day 15, day 57
|
Maximum blood glucose concentration
|
day 1, day 8, day 15, day 57
|
|
Max-Increase
Time Frame: day 1, day 8, day 15, day 57
|
Cmax minus baseline value
|
day 1, day 8, day 15, day 57
|
|
Tmax
Time Frame: day 1, day 8, day 15, day 57
|
Time to reach maximum blood glucose concentration
|
day 1, day 8, day 15, day 57
|
|
Tbaseline
Time Frame: day 1, day 8, day 15, day 57
|
First time to reach baseline again after increase or decrease in blood glucose
|
day 1, day 8, day 15, day 57
|
|
AUC(0-180min):
Time Frame: day 1, day 8, day 15, day 57
|
Total area under curve from 0 to 180 min for blood glucose concentration
|
day 1, day 8, day 15, day 57
|
|
Insulin-iAUC(0-180min)
Time Frame: day 1, day 8, day 15, day 57
|
Area under the curve calculated as the incremental area under the Insulin response curve, ignoring the area beneath the fasting concentration
|
day 1, day 8, day 15, day 57
|
|
Cmax Baseline Insulin Max_increase Insulin
Time Frame: day 1, day 8, day 15, day 57
|
Max_increase Insulin Cmax minus baseline insulin value
|
day 1, day 8, day 15, day 57
|
|
Tmax insulin
Time Frame: day 1, day 8, day 15, day 57
|
time to reach maximum Insulin concentration
|
day 1, day 8, day 15, day 57
|
|
Fasting glucose, fasting insulin
Time Frame: Baseline and Day 57
|
Baseline and Day 57
|
|
|
HOMA index
Time Frame: Baseline and Day 57
|
Parameters of insulin sensitivity:
|
Baseline and Day 57
|
|
HbA1c level
Time Frame: Baseline (V5) and Day 57 (after 6 weeks)
|
HbA1c level after 6 weeks of supplementation
|
Baseline (V5) and Day 57 (after 6 weeks)
|
|
Matsuda index
Time Frame: Baseline and Day 57
|
Insulin sensitivity
|
Baseline and Day 57
|
|
Quicki Index
Time Frame: Baseline and Day 57
|
Insulin sensitivity
|
Baseline and Day 57
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Audrey BOULIER, MD, Ingredia S.A.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BTS1130/17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.